清華大學(xué)醫(yī)學(xué)院Charles David實驗室2018招聘癌癥生物學(xué)博士后

清華大學(xué)醫(yī)學(xué)院 Charles David實驗室招聘癌癥生物學(xué)博士后(2-3名) 時間：2018-01-03

清華大學(xué)醫(yī)學(xué)院 Charles David實驗室招聘癌癥生物學(xué)博士后(2-3名)

Charles David(戴超)實驗室具有清華北大聯(lián)合中心的支持。本實驗室運用多種新穎的實驗手段鑒定主宰癌癥細(xì)胞和組織干細(xì)胞命運的轉(zhuǎn)錄因子以及轉(zhuǎn)錄網(wǎng)絡(luò)。研究鑒定癌信號通路如何通過挾持干細(xì)胞的轉(zhuǎn)錄網(wǎng)絡(luò)誘導(dǎo)癌癥發(fā)生 。

清華博士后享受有競爭力的待遇。實驗室支持申請各類博士后基金如CLS博士后基金、大學(xué)博士后支持計劃等.

招聘條件

1.具有分子和細(xì)胞生物學(xué), 生物化學(xué), 或者癌癥學(xué)相關(guān)專業(yè)博士學(xué)位，獲得博士學(xué)位2年以內(nèi)；

2.近3年以來，以第一作者身份在國際知名學(xué)術(shù)期刊發(fā) （IF > 5) 表過研究論文；

3.具有較高的英語寫作及口語交流能力.

申請材料及申請方式 ：

1個人簡歷；

2個人陳述 （研究背景，個人事業(yè)目標(biāo)等；中英均可）；

3兩名推薦人的聯(lián)系方式。

請將申請材料發(fā)至：cdavid@mail.tsinghua.edu

Charles David’s Lab at Tsinghua University School of Medicine recruiting 2-3 postdoctoral fellows

The David laboratory is supported in part by the Peking-Tsinghua Center for Life Sciences (CLS). The laboratory uses cutting-edge approaches to parse essential tumorigenic transcriptional networks in cancer as well as the stem/progenitor cells that can serve as the cell of origin for neoplasms. The laboratory is also focused on understanding the specific molecular interactions between oncogenic signaling pathways and stem/progenitor-derived transcriptional networks.

Tsinghua University postdoctoral fellows enjoy competitive pay and benefits, and are able to apply for a wide range of additional support available at Tsinghua/CLS.

The successful candidate(s) will:

1. have a Ph.D. in the areas of molecular/cellular biology, biochemistry, epigenetics, or cancer biology within the last two years;

2. have published a first author paper in a reputable journal (IF > 5) in the past three years; AND

3. have proficiency in verbal and written English.

Applicants should supply:

1. an up-to-date CV;

2. a personal statement (detailing research experience, career goals etc.); AND

3. contact information for two references.

Please send application materials to: cdavid@mail.tsinghua.edu.

戴超代表成果如下：

1.David CJ, Huang YH, Chen M, Su J, Bardeesy N, Iacobuzio-Donahue CA, Massagué J (2016) TGF-β tumor suppression through a lethal EMT.Cell164(5):1015-30.

2.David CJ, Boyne AB, Millhouse SR, Manley JL (2011). The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex.Genes and Development25: 972-83.

3.David CJ, Manley JL (2010). Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.Genes and Development24: 2324-64.

4.David CJ*, Chen M*, Assanah M, Canoll P, Manley JL (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.Nature463: 364-8.*Co-first author

5.David CJ, Manley JL (2008). The search for alternative splicing regulators: new approaches offer a path to a splicing code.Genes and Development22: 279-85.